EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Efficacy and Safety of Haploidentical Hematopoietic Stem Cell Transplantation Combined With Umbilical Cord Blood Infusion in Hematologic Malignancies: A Prospective Phase II Clinical Trial

Jiejing Qian, Xianbo Huang, Chen Mei, Yanling Ren, Cuihua Fan, Guifang Ouyang, Shasha Wang, Yu Xu, Sujing Zhuang, Weijuan Yang, Jie Jin, Hongyan Tong

Transplantation and Cellular Therapy · 2025-12 · 31 (12) · 1035.e1-1035.e12

DOI: 10.1016/j.jtct.2025.09.005 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Transplantation and Cellular Therapy, 2025-12. Verfasst von Jiejing Qian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Clinical Resear…. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Cord Blood Stem Cell Transplantation, Transplantation, Haploidentical. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) offers curative potential for hematologic malignancies but is often limited by high incidences of graft-versus-host disease (GVHD), delayed engraftment, and transplant-related mortality-especially when donors are aged ≥40 years. Umbilical cord blood (UCB) infusion may mitigate these risks by promoting immune tolerance and hematopoietic recovery. However, the efficacy of this strategy in the context of older donors remains insufficiently studied. OBJECTIVES: This study aimed to evaluate the efficacy and safety of combining UCB infusion with haplo-HSCT using older (≥40 years) haploidentical donors in patients with hematologic malignancies. STUDY DESIGN: This was a multicenter, prospective, single-arm phase II clinical trial registered in the Chinese Clinical Trial Registry (ChiCTR2200062553). A total of 45 patients diagnosed with myeloid or lymphoid malignancies received haplo-HSCT with donors aged ≥40 years, followed by UCB infusion within 24 hours. The primary endpoint was the cumulative incidence of grade II-IV acute GVHD by day +100. Secondary endpoints included hematopoietic engraftment, overall survival (OS), disease-free survival (DFS), GVHD-free, relapse-free survival (GRFS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and adverse events (AEs). RESULTS: All patients achieved neutrophil engraftment (median: 12 days) and most achieved platelet engraftment (median: 13 days). Grade II-IV and III-IV acute GVHD occurred in 22.29% and 8.89% of patients, respectively. The 2-year CIR and NRM were 11.49% and 2.44%, respectively. The estimated 2-year OS, DFS, and GRFS were 95.39%, 86.24%, and 76.59%, respectively. Infectious complications were manageable, and adverse events were consistent with expectations for this patient population. CONCLUSIONS: Haplo-HSCT combined with UCB infusion is a safe and effective strategy for patients lacking young donors, offering rapid hematopoietic recovery, low GVHD incidence, and favorable survival outcomes. This approach provides a viable option for donor-limited settings and supports broader application of haploidentical transplantation in aging populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematologic NeoplasmsHematopoietic Stem Cell TransplantationCord Blood Stem Cell TransplantationTransplantation, HaploidenticalFetal BloodHumansMaleFemaleAdultMiddle AgedProspective StudiesGraft vs Host DiseaseAgedTreatment Outcome

Stichwörter der Autor:innen

Haploidentical hematopoietic stem cell transplantationHematological malignancies;Cell therapyUmbilical cord blood

Autor:innen und Institutionen

  • Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China; Zhejiang Provincial Clinical Research Center for Hematological disorders, Hangzhou, China; Zhejiang Key L…
  • Department of hematology, Shulan (Hangzhou) Hospital, Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China.
  • Department of hematology, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Department of R&D/application, Shandong cord blood bank (Shandong Qilu Stem Cell Engineering Co.LTD, Jinan, China.

Zitieren

APA

Qian, J., Huang, X., Mei, C., Ren, Y., Fan, C., Ouyang, G., Wang, S., Xu, Y., Zhuang, S., Yang, W., Jin, J., & Tong, H. (2025). Efficacy and Safety of Haploidentical Hematopoietic Stem Cell Transplantation Combined With Umbilical Cord Blood Infusion in Hematologic Malignancies: A Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy, 31(12), 1035.e1-1035.e12. https://doi.org/10.1016/j.jtct.2025.09.005

Vancouver

Qian J, Huang X, Mei C, Ren Y, Fan C, Ouyang G, et al. Efficacy and Safety of Haploidentical Hematopoietic Stem Cell Transplantation Combined With Umbilical Cord Blood Infusion in Hematologic Malignancies: A Prospective Phase II Clinical Trial. Transplantation and Cellular Therapy. 2025;31(12):1035.e1-1035.e12. doi:10.1016/j.jtct.2025.09.005

BibTeX
@article{Qian2025,
  author = {Qian, Jiejing and Huang, Xianbo and Mei, Chen and Ren, Yanling and Fan, Cuihua and Ouyang, Guifang and Wang, Shasha and Xu, Yu and Zhuang, Sujing and Yang, Weijuan and Jin, Jie and Tong, Hongyan},
  title = {Efficacy and Safety of Haploidentical Hematopoietic Stem Cell Transplantation Combined With Umbilical Cord Blood Infusion in Hematologic Malignancies: A Prospective Phase II Clinical Trial},
  journal = {Transplantation and Cellular Therapy},
  year = {2025},
  volume = {31},
  number = {12},
  pages = {1035.e1--1035.e12},
  doi = {10.1016/j.jtct.2025.09.005}
}
Kostenlos starten →